000			01761 a2200433 4500
005			20250515161157.0
264		0	_c20090421
008			200904s 0 0 eng d
022			_a1550-6606
024	7		_a10.4049/jimmunol.0803585 _2doi
040			_aNLM _beng _cNLM
100	1		_aOlson, Matthew R
245	0	0	_aFas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease. _h[electronic resource]
260			_bJournal of immunology (Baltimore, Md. : 1950) _cMar 2009
300			_a3024-31 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural
650	0	4	_aAdjuvants, Immunologic _xadministration & dosage
650	0	4	_aAnimals
650	0	4	_aAutoimmune Diseases _xgenetics
650	0	4	_aCD4-Positive T-Lymphocytes _ximmunology
650	0	4	_aCD8-Positive T-Lymphocytes _ximmunology
650	0	4	_aCell Differentiation _xgenetics
650	0	4	_aEpitopes, T-Lymphocyte _ximmunology
650	0	4	_aFas Ligand Protein _xbiosynthesis
650	0	4	_aHumans
650	0	4	_aImmunization, Secondary
650	0	4	_aImmunologic Memory _xgenetics
650	0	4	_aLymphatic Diseases _xgenetics
650	0	4	_aMice
650	0	4	_aMice, Inbred BALB C
650	0	4	_aMice, Mutant Strains
650	0	4	_aPulmonary Eosinophilia _xgenetics
650	0	4	_aRespiratory Syncytial Virus Vaccines _xadministration & dosage
650	0	4	_aRespiratory Syncytial Viruses _ximmunology
650	0	4	_aViral Envelope Proteins _xadministration & dosage
700	1		_aVarga, Steven M
773	0		_tJournal of immunology (Baltimore, Md. : 1950) _gvol. 182 _gno. 5 _gp. 3024-31
856	4	0	_uhttps://doi.org/10.4049/jimmunol.0803585 _zAvailable from publisher's website
999			_c18676554 _d18676554